BRIEF-Rhythm Pharmaceuticals Says Phase 2 Signal Trial Shows Bivamelagon Reduces BMI In Hypothalamic Obesity

Reuters
13 Jul
BRIEF-Rhythm Pharmaceuticals Says Phase 2 Signal Trial Shows Bivamelagon Reduces BMI In Hypothalamic Obesity

July 12 (Reuters) - Rhythm Pharmaceuticals Inc RYTM.O:

  • RHYTHM PHARMACEUTICALS INC - PHASE 2 SIGNAL TRIAL SHOWS BIVAMELAGON REDUCES BMI IN HYPOTHALAMIC OBESITY

  • RHYTHM PHARMACEUTICALS INC - PHASE 3 TRANSCEND TRIAL SHOWS SETMELANOTIDE REDUCES BMI IN HYPOTHALAMIC OBESITY

Source text: ID:nGNXbDqsNv

Further company coverage: RYTM.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10